from The Scientist, June 2022 Issue 2
Nasal Vaccines Are Commercially High Risk, Perhaps High Reward
Previous
Previous
Blue Lake Biotechnology Announces First Participant Dosed in a Phase 1 Clinical Trial of Its BLB-201 Intranasal RSV Vaccine
Next
Next